Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

S Ida, R Kaneko, K Murata - Cardiovascular Diabetology, 2019 - Springer
Background Using a meta-analysis of randomized controlled trials (RCTs), this study aimed
to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome …

Fibrates in the management of atherogenic dyslipidemia

B Okopień, L Buldak, A Bołdys - Expert review of cardiovascular …, 2017 - Taylor & Francis
Introduction: Significant advancements in the treatment of hypercholesterolemia have
recently been achieved. However, a considerable level of residual cardiovascular risk still …

Dysfunctional HDL as a therapeutic target for atherosclerosis prevention

A Ossoli, C Pavanello, E Giorgio… - Current medicinal …, 2019 - ingentaconnect.com
Hypercholesterolemia is one of the main risk factors for the development of atherosclerosis.
Among the various lipoprotein classes, however, high density lipoproteins (HDL) are …

Endothelial dysfunction in dyslipidaemia: molecular mechanisms and clinical implications

B Zaric, M Obradovic, A Trpkovic… - Current Medicinal …, 2020 - ingentaconnect.com
The endothelium consists of a monolayer of Endothelial Cells (ECs) which form the inner
cellular lining of veins, arteries, capillaries and lymphatic vessels. ECs interact with the …

Endothelium as a therapeutic target in diabetes mellitus: from basic mechanisms to clinical practice

A Tentolouris, I Eleftheriadou… - Current medicinal …, 2020 - ingentaconnect.com
Endothelium plays an essential role in human homeostasis by regulating arterial blood
pressure, distributing nutrients and hormones as well as providing a smooth surface that …

Effect of fenofibrate on uric acid level in patients with gout

JY Jung, Y Choi, CH Suh, D Yoon, HA Kim - Scientific Reports, 2018 - nature.com
Gout is a chronic disease associated with deposition of monosodium urate crystals and
accompanied by diabetes, hypertension, and dyslipidemia. Hypertriglyceridemia is common …

[HTML][HTML] Influence of lipid-lowering drugs on inflammation: what is yet to be done?

S Ugovšek, J Zupan, AR Likozar… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Atherosclerosis is a chronic inflammatory disease that is associated with risk of
cardiovascular events. The best-characterised and well-standardised clinical indicator of …

[HTML][HTML] Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical …

ME Rubio-Ruíz, JC Plata-Corona, E Soria-Castro… - Cells, 2024 - mdpi.com
Cardiovascular diseases remain the leading cause of death in the world, and that is why
finding an effective and multi-functional treatment alternative to combat these diseases has …

[PDF][PDF] Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function

M Gomaraschi, MP Adorni, M Banach… - High Density …, 2015 - library.oapen.org
The knowledge of an inverse relationship between plasma high-density lipoprotein
cholesterol (HDL-C) concentrations and rates of cardiovascular disease has led to the …

Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional …

RAK Srivastava, JA Cornicelli, B Markham… - Molecular and Cellular …, 2018 - Springer
Inflammation plays a key role in setting the stage leading to atherosclerosis progression,
and high-sensitivity C-reactive protein (CRP) has been recognized as a predictor of …